BD Acquires GenCell Biosystems

Becton, Dickinson and Company (BD) has announced its acquisition of GenCell Biosystems.

GenCell Biosystems is a privately-held Irish biotech company that develops proprietary technologies to address key biological analysis including next-generation sequencing (NGS).

BD Group President Linda Tharby said: "We are excited with the GenCell Biosystems acquisition as it provides BD entry into the NGS market, a fast-growing segment with the potential to have a significant impact on healthcare."

GenCell’s headquarters and manufacturing are based in Limerick, Ireland. The company operates a US marketing, sales and service group in Madison, Wisconsin.

Founded in 2011, GenCell created an automated platform, with the potential to address key unmet customer needs in library preparation for next-generation sequencing.

GenCell CEO Kieran Curran said: "In a short amount of time we have been able to move chemical looping combustion (CLC) technology from concept to product.

"We believe we will now be able to scale up and introduce further transformative innovation in NGS-related segments."
Financial details on the acquisition are not disclosed.

More About This Company